Cattarino Susanna, Seisen Thomas, Drouin Sarah J, Renard-Penna Raphaële, Leon Priscilla, Comperat Eva, Mozer Pierre, Cussenot Olivier, Rouprêt Morgan
Hopital Pitié-Salpétrière, Academic Department of Urology, Paris, France.
Can J Urol. 2015 Apr;22(2):7703-8.
To assess the impact of statin use on biochemical recurrence (BCR) of prostate cancer after radical prostatectomy (RP).
Data from all men treated with robot-assisted laparoscopic RP (RALRP) for localized prostate cancer between 2009 and 2014 at our institution were prospectively collected: age, body mass index (BMI), statin-use status, preoperative prostate-specific antigen (PSA) level, clinical T stage, biopsy Gleason score (bGS), D'Amico risk group, pathological T stage, specimen Gleason score (sGS), multifocality, peri neural invasion, positive surgical margins and time to BCR. Univariate and multivariate analysis were performed to test associations between statin use and prognostic factors of prostate cancer and/or BCR.
Overall, 591 patients with a median follow up of 42.3 months [25.8-59.9] were included in the current study and split in two cohorts: statin users (n = 156) and statin non-users (n = 435). When comparing statin user and non-users, no significant difference was found in terms of clinical, biochemical and pathological characteristics except for BMI (median 29 versus 26, respectively; p = 0.04). Regarding BCR, there was no significant difference between men using statin versus those not using them (4.5% versus 4.6%, p = 0.65). In univariate analysis, statin use was not significantly correlated to any prognostic factors of prostate cancer recurrence. Furthermore, there was no significant difference in the 5 years biochemical-free survival rates between statin users and non-users (75% versus 73%; p = 0.7).
From the current study, statin daily intake was not significantly associated with any prognostic factors of prostate cancer and with BCR after RARLP.
评估他汀类药物的使用对前列腺癌根治术后生化复发（BCR）的影响。
前瞻性收集了2009年至2014年在我院接受机器人辅助腹腔镜前列腺癌根治术（RALRP）治疗的所有男性患者的数据：年龄、体重指数（BMI）、他汀类药物使用情况、术前前列腺特异性抗原（PSA）水平、临床T分期、活检Gleason评分（bGS）、D'Amico风险组、病理T分期、标本Gleason评分（sGS）、多灶性、神经周围侵犯、手术切缘阳性以及至BCR的时间。进行单因素和多因素分析以检验他汀类药物使用与前列腺癌和/或BCR预后因素之间的关联。
总体而言，本研究纳入了591例患者，中位随访时间为42.3个月[25.8 - 59.9]，并分为两个队列：他汀类药物使用者（n = 156）和非使用者（n = 435）。比较他汀类药物使用者和非使用者时，除BMI外，在临床、生化和病理特征方面未发现显著差异（中位值分别为29和26；p = 0.04）。关于BCR，使用他汀类药物的男性与未使用他汀类药物的男性之间无显著差异（4.5%对4.6%，p = 0.65）。在单因素分析中，他汀类药物的使用与前列腺癌复发的任何预后因素均无显著相关性。此外，他汀类药物使用者和非使用者之间的5年无生化复发生存率无显著差异（75%对73%；p = 0.7）。
从本研究来看，每日服用他汀类药物与前列腺癌的任何预后因素以及RALRP术后的BCR均无显著关联。
